Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: a post hoc analysis based on a phase III trial

Frontiers in Pharmacology 2026 Open access

Read full text
Authors: Xiunan Wang, L. Li
DOI: 10.3389/fphar.2025.1685072
Cited by: 2
References: 36

Abstract

Objective Vunakizumab is effective and safe for treating moderate-to-severe plaque psoriasis patients. This post hoc analysis was intended to assess the effects of vunakizumab in patients with different body mass index (BMI). Methods In the phase III trial of vunakizumab (NCT04839016), 461 moderate-to-severe plaque psoriasis patients receiving vunakizumab were enrolled and categorized into baseline BMI

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments Rheumatoid Arthritis Research and Therapies

Publication details

Journal / source
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Volume
16
Pages
1685072–1685072
Publication date
6 January 2026
Language
EN